LCB14-2516 / LG Chem - LARVOL DELTA

Preclinical Evaluation of ?-Glucuronide Linker-Based BCMA Adcs with MMAF, Propbd, and TOP1 Inhibitor Payloads Support Differentiated Clinical Development Strategies (IMS 2026) - "Introduction: Belantamab mafodotin combination therapies have demonstrated the potential of BCMA-targeted antibody-drug conjugates (ADCs) in the multiple myeloma treatment landscape, yet are limited by the prevalence of ocular toxicity. LCB14-2524 (LBG-MMAF), LCB14-2516 (LBG-proPBD), and LCB43-101001 (Novel TOP1i) all demonstrated preclinical profiles supporting further development. LCB14-2524 has been prioritized for first clinical assessment based on the combination of pre-clinical profile and clinical experience with the platform linker-payload (FS-1502/IKS014). LCB14-2516 or LCB43-101001 provide differentiated follow-on opportunities to introduce new payload mechanism into the multiple myeloma treatment landscape."

Preclinical • Hematological Malignancies • Multiple Myeloma • Ophthalmology • TOP1

Next generation ConjuAll BCMA antibody-drug conjugates (ADCs) LCB14-2524 and LCB14-2516 show increased efficacy in preclinical models of multiple myeloma (AACR 2026) - "This target has emerged as one of the most important for targeted therapies in relapsed/refractory multiple myeloma (RRMM) as demonstrated by the recent approval of the ADC belantamab mafodotin in combination with bortezomib and dexamethasone. In vivo, both LCB14-2516 (LBG-proPBD) and LCB14-2524 (LBG-MMAF) were more active than the belantamab mafodotin biosimilar across OPM2, MM.1S and NCI-H929 CDX models. Both LCB14-2516 (LBG-proPBD) and LCB14-2524 (LBG-MMAF) ADCs utilize clinically validated LCB technology with promise to increase the therapeutic index of BCMA targeted ADCs and are progressing through IND enabling studies for clinical development."

ADC • Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology

LigaChem Bio announced on March 18 that it will present research findings on its BCMA ADC pipelines, 'LCB14-2524' and 'LCB14-2516' (development codes), in poster format at the American Association for Cancer Research (AACR 2026), scheduled to take place in San Diego, USA, from April 17 to 22 (local time). (The Bio) - "LigaChem Bio reported that both candidates demonstrated superior cytotoxicity and efficacy compared to the control group, Blenrep, in preclinical evaluations."

Preclinical • Multiple Myeloma